Purpose
Outline new or updated vaccine recommendations that have occurred since October 24, 2024.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Addendum
In addition to the recommendations presented in the previous sections of this immunization schedule, CDC has approved the following ACIP recommendations since October 24, 2024.
| Vaccines | Recommendations | Effective Date of Recommendation† |
|---|---|---|
| Meningococcal (MenACWY-CRM/ MenB-4C, Penmenvy) | ACIP recommends GSK's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the
same visit*
*(1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and (2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).
|
June 25, 2025 |
| RSV (Abrysvo,Arexvy,mResvia) | ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV diseasea receive a single dose of RSV vaccine.b,c
|
June 25, 2025 |
†The effective date is the date when the recommendation was adopted and became official.